Product image of Mycophenolatmofetil Stada (Mycophenolate Mofetil) supplied by GNH India

Mycophenolatmofetil Stada

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycophenolatmofetil Stada (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Stada, is an immunosuppressant presented as an oral formulation for oral use. It is used to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis in adult patients.

GNH India supplies Mycophenolatmofetil Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Mofetil is employed in immunosuppressive regimens for organ transplantation and selected autoimmune disorders.

  • Kidney transplant rejection: lowers the incidence of acute rejection episodes.
  • Heart transplant rejection: helps maintain graft function and prolong survival.
  • Lupus nephritis: contributes to remission of renal inflammation and preservation of kidney function.

How It Works

  • Mycophenolate Mofetil is a pro‑drug that is converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). By blocking IMPDH, the drug impairs de novo synthesis of guanosine nucleotides, a pathway essential for proliferation of T and B lymphocytes, thereby reducing immune activation and graft rejection.

Side Effects

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools, may lead to dehydration.
  • Headache: transient and usually resolves.
  • Abdominal pain: cramping or discomfort.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects

  • Bone marrow suppression: leukopenia, anemia or thrombocytopenia.
  • Severe infections: opportunistic infections such as CMV or PCP.
  • Hepatic dysfunction: elevated transaminases or hepatitis.
  • Malignancy: increased risk of post‑transplant lymphoproliferative disorder.
  • Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.
  • Pregnancy loss: potential teratogenic effects.

Precautions & Warnings

Careful monitoring and patient education are essential when using Mycophenolate Mofetil.

  • Monitor blood counts: perform regular CBC to detect cytopenias.
  • Assess liver function: check transaminases periodically.
  • Avoid live vaccines: immunosuppression can cause vaccine‑derived infection.
  • Pregnancy safety: discontinue if pregnancy is confirmed; discuss contraception.
  • Renal impairment: dose adjustment may be required in reduced kidney function.
  • Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Mycophenolate Mofetil may interact with several concomitant medicines, influencing efficacy or toxicity.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression.
  • Cyclosporine or tacrolimus: increased mycophenolic acid exposure, risk of toxicity.
  • Rifampin: markedly reduces mycophenolic acid levels, compromising efficacy.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours.
  • Warfarin: potential alteration of INR; monitor coagulation parameters.
  • Live attenuated vaccines: heightened risk of infection; consider alternative immunization strategies.

Frequently Asked Questions

Mycophenolatmofetil Stada contains mycophenolate mofetil, an immunosuppressant used primarily to prevent rejection after kidney, heart or liver transplantation and to treat autoimmune conditions such as lupus nephritis in adult patients.

Mycophenolate mofetil is converted in the body to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase. This inhibition stops the synthesis of guanosine nucleotides needed for T‑ and B‑cell proliferation, thereby dampening the immune response.

The prescribed dose of Mycophenolatmofetil Stada is determined by the treating physician based on the patient’s condition, transplant type, renal function and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

The safety of mycophenolate mofetil in pregnancy is not established and it is generally contraindicated because of potential teratogenic effects. Women of child‑bearing potential should use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—targeting lymphocyte proliferation rather than cytokine production. It is often used in combination regimens to achieve synergistic immunosuppression while allowing lower doses of each agent.

Mycophenolatmofetil Stada should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources to maintain product stability.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Doses are often divided into two daily administrations to maintain steady blood levels, but the exact schedule is individualized.

Serious risks include bone‑marrow suppression leading to severe infections, hepatic injury, and rare but life‑threatening conditions such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for blood counts, liver enzymes and signs of infection.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in pregnant women, those receiving live vaccines, and individuals with severe uncontrolled infections without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT